Testing a 3-drug combination for better blood sugar control
Part of Hormones & metabolism clinical trials.
This study tests a combination of three diabetes medicines (empagliflozin, linagliptin, and metformin) to see if it helps control blood sugar in people with type 2 diabetes. It may be an option if your current treatment isn't working well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with type 2 diabetes for at least 6 months.
- Your recent HbA1c (a measure of average blood sugar over 2-3 months) is 8% or higher.
- You are already taking 2 or more other diabetes medicines.
- You are not allergic to empagliflozin, linagliptin, or metformin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different combinations of diabetes pills (metformin plus empagliflozin with either sitagliptin or linagliptin) in people with type 2 diabetes who have not been treated before. It aims to see which combination works better and is safer for controlling blood sugar.
This trial tests a combination of three diabetes medicines (dapagliflozin, linagliptin, and metformin) in healthy adults to see how safe they are and how the body processes them. Participating could help make sure these medicines are safe for people with diabetes.
This trial is testing different combinations of diabetes medicines to see which one helps keep your blood sugar more steady throughout the day. It's for people with type 2 diabetes who are already taking metformin and an SGLT-2 inhibitor but still have high blood sugar.
This trial tests a combination of three diabetes medicines (henagliflozin proline, retagliptin, and metformin) for people newly diagnosed with type 2 diabetes. The goal is to see how well the combination controls blood sugar and to check its safety.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
This trial tests a combination of three common diabetes medications (metformin, an SGLT2 inhibitor, and a TZD) to see how well they work together and if they are safe. It may help people with type 2 diabetes who need better blood sugar control.
Hear when a new Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.